Shaoyu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaoyu Liu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Jiawei Zhong
Department of Nuclear Medicine
4 shared publications- Xinlu Wang
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
4 shared publications Ziqi Zhang
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
3 shared publicationsLifang Liu
Nuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publicationsRuiyue Zhao
Department of Nuclear Medicine
2 shared publicationsXiaoting Ye
Nuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications
Latest Publications
- 29 April 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (8) , 4037-4047
Development and Preclinical Evaluation of Dual-Target 68 Ga/ 177 Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention
Bone metastases and associated skeletal-related events (SREs) severely compromise the survival and quality of life of patients with advanced cancer. Although bisphosphonates enable efficient bone targeting, their radiolabeled analogues exhibit limited uptake in osteolytic lesions due to the low hydroxyapatite content. Fibroblast activation protein, highly expressed in cancer-associated fibroblasts within the tumor microenvironment, provides tumor specificity and may enhance tracer accumulation in osteolytic bone metastases. To overcome this limitation, we developed two heterodimeric [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-bisphosphonate radioligands ([68Ga]Ga/[177Lu]Lu-DFP-1/2) by integrating a FAP-targeting moiety with a bisphosphonate backbone. Both compounds were synthesized with high radiochemical purity (>95%) and excellent in vitro stability. In A549-FAP xenograft models, dynamic PET/CT imaging revealed comparable tumor uptake of [68Ga]Ga-DFP-1/2 and [68Ga]Ga-FAPI-04 up to 2 h postinjection, with [68Ga]Ga-DFP-2 demonstrating faster clearance from nontarget organs. In tibial A549-FAP osteogenic models, [68Ga]Ga-DFP-2 showed significantly higher uptake (4.88 ± 1.01% ID/mL) than mono-FAP or monobisphosphonate tracers (p < 0.05). In osteolytic A549 models, [68Ga]Ga-DFP-2 uptake (3.16 ± 0.82% ID/mL) also exceeded that of monobisphosphonate tracers (p < 0.01). Biodistribution studies confirmed prolonged [177Lu]Lu-DFP-2 retention (26.94 ± 4.40% ID/g at 168 h). Collectively, these findings demonstrate that [68Ga]Ga/[177Lu]Lu-DFP-2 possesses favorable dual bone- and tumor-targeting characteristics and holds strong translational promise as a novel theranostic agent for the imaging and treatment of lung cancer bone metastases.
- 29 April 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (8) , 4037-4047
Development and Preclinical Evaluation of Dual-Target 68 Ga/ 177 Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention
Bone metastases and associated skeletal-related events (SREs) severely compromise the survival and quality of life of patients with advanced cancer. Although bisphosphonates enable efficient bone targeting, their radiolabeled analogues exhibit limited uptake in osteolytic lesions due to the low hydroxyapatite content. Fibroblast activation protein, highly expressed in cancer-associated fibroblasts within the tumor microenvironment, provides tumor specificity and may enhance tracer accumulation in osteolytic bone metastases. To overcome this limitation, we developed two heterodimeric [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-bisphosphonate radioligands ([68Ga]Ga/[177Lu]Lu-DFP-1/2) by integrating a FAP-targeting moiety with a bisphosphonate backbone. Both compounds were synthesized with high radiochemical purity (>95%) and excellent in vitro stability. In A549-FAP xenograft models, dynamic PET/CT imaging revealed comparable tumor uptake of [68Ga]Ga-DFP-1/2 and [68Ga]Ga-FAPI-04 up to 2 h postinjection, with [68Ga]Ga-DFP-2 demonstrating faster clearance from nontarget organs. In tibial A549-FAP osteogenic models, [68Ga]Ga-DFP-2 showed significantly higher uptake (4.88 ± 1.01% ID/mL) than mono-FAP or monobisphosphonate tracers (p < 0.05). In osteolytic A549 models, [68Ga]Ga-DFP-2 uptake (3.16 ± 0.82% ID/mL) also exceeded that of monobisphosphonate tracers (p < 0.01). Biodistribution studies confirmed prolonged [177Lu]Lu-DFP-2 retention (26.94 ± 4.40% ID/g at 168 h). Collectively, these findings demonstrate that [68Ga]Ga/[177Lu]Lu-DFP-2 possesses favorable dual bone- and tumor-targeting characteristics and holds strong translational promise as a novel theranostic agent for the imaging and treatment of lung cancer bone metastases.
- Open Access
- 1 October 2024
- Published by Springer Nature in EJNMMI Research
- Vol. 14 (1) , 1-11
Preclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts
Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. [68Ga]Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel [18F]F-labeled FAP-targeting peptide. [18F]AlF-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to [68Ga]Ga-FAP-2286, the [18F]F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, [18F]AlF-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of [18F]AlF-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. Based on the physical imaging properties and longer half-life of [18F]F, [18F]AlF-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation. www.Chictr.org.cn , ChiCTR2300076976 Retrospectively registered 25 October 2023. at, URL: https://www.chictr.org.cn/showproj.html?proj=206753 .
- 1 October 2024
- Published by Springer Nature in EJNMMI Research
- Vol. 14 (1) , 1-11
Open AccessPreclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts
Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. [68Ga]Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel [18F]F-labeled FAP-targeting peptide. [18F]AlF-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to [68Ga]Ga-FAP-2286, the [18F]F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, [18F]AlF-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of [18F]AlF-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. Based on the physical imaging properties and longer half-life of [18F]F, [18F]AlF-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation. www.Chictr.org.cn , ChiCTR2300076976 Retrospectively registered 25 October 2023. at, URL: https://www.chictr.org.cn/showproj.html?proj=206753 .
- 24 June 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (12) , 3651-3661
[64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window
Background The aim of the present study was to develop a novel 64Cu-labeled cyclic peptide ([64Cu]Cu-FAP-NOX) that targets fibroblast activation protein (FAP) and may offer advantages in terms of image contrast, imaging time window, and low uptake in normal tissues. Methods The novel cyclic peptide featuring with a N-oxalyl modified tail was constructed and conjugated to NOTA for 64Cu labeling. Biochemical and cellular assays were performed with A549.hFAP cells. The performance of [64Cu]Cu-FAP-NOX was compared to that of two established tracers ([64Cu]Cu-FAPI-04 and [68Ga]Ga-FAP-2286) and three different NOTA-conjugates in HEK-293T.hFAP xenograft mice using micro-PET imaging. Ex vivo biodistribution studies were performed to confirm the FAP specificity and to validate the PET data. Furthermore, a first-in-human study of this novel tracer was conducted on one patient with lung cancer. Results Compared to [64Cu]Cu-FAPI-04, [64Cu]Cu-FAP-NOX demonstrated faster and higher rates of cellular uptake and internalization in A549.hFAP cells, but lower rates of cellular efflux. All six radiotracers were rapidly taken up by the tumor within the first 4 h post-injection. However, [64Cu]Cu-FAP-NOX had more intense tumor accumulation and slower washout from the target. The ratios of the tumor to normal tissue (including kidneys and muscles) increased significantly over time, with [64Cu]Cu-FAP-NOX reaching the highest ratio among all tracers. In the patient, [64Cu]Cu-FAP-NOX PET showed a comparable result to FDG PET in the primary malignant lesion while exhibiting higher uptake in pleural metastases, consistent with elevated FAP expression as confirmed by immunohistochemistry. Conclusion [64Cu]Cu-FAP-NOX is a promising FAP-targeted tracer with a highly flexible imaging time window, as evidenced by preclinical evaluation encompassing biodistribution and micro-PET studies, along with a successful patient application. Furthermore, [64Cu]Cu-FAP-NOX showed enhanced image contrast and favorable pharmacokinetic properties for FAP PET imaging, warranting translation into large cohort studies.
- 24 June 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (12) , 3651-3661
[64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window
Background The aim of the present study was to develop a novel 64Cu-labeled cyclic peptide ([64Cu]Cu-FAP-NOX) that targets fibroblast activation protein (FAP) and may offer advantages in terms of image contrast, imaging time window, and low uptake in normal tissues. Methods The novel cyclic peptide featuring with a N-oxalyl modified tail was constructed and conjugated to NOTA for 64Cu labeling. Biochemical and cellular assays were performed with A549.hFAP cells. The performance of [64Cu]Cu-FAP-NOX was compared to that of two established tracers ([64Cu]Cu-FAPI-04 and [68Ga]Ga-FAP-2286) and three different NOTA-conjugates in HEK-293T.hFAP xenograft mice using micro-PET imaging. Ex vivo biodistribution studies were performed to confirm the FAP specificity and to validate the PET data. Furthermore, a first-in-human study of this novel tracer was conducted on one patient with lung cancer. Results Compared to [64Cu]Cu-FAPI-04, [64Cu]Cu-FAP-NOX demonstrated faster and higher rates of cellular uptake and internalization in A549.hFAP cells, but lower rates of cellular efflux. All six radiotracers were rapidly taken up by the tumor within the first 4 h post-injection. However, [64Cu]Cu-FAP-NOX had more intense tumor accumulation and slower washout from the target. The ratios of the tumor to normal tissue (including kidneys and muscles) increased significantly over time, with [64Cu]Cu-FAP-NOX reaching the highest ratio among all tracers. In the patient, [64Cu]Cu-FAP-NOX PET showed a comparable result to FDG PET in the primary malignant lesion while exhibiting higher uptake in pleural metastases, consistent with elevated FAP expression as confirmed by immunohistochemistry. Conclusion [64Cu]Cu-FAP-NOX is a promising FAP-targeted tracer with a highly flexible imaging time window, as evidenced by preclinical evaluation encompassing biodistribution and micro-PET studies, along with a successful patient application. Furthermore, [64Cu]Cu-FAP-NOX showed enhanced image contrast and favorable pharmacokinetic properties for FAP PET imaging, warranting translation into large cohort studies.
- 8 February 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (7) , 2012-2022
Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients
Purpose Fibroblast-activated protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of many solid cancers, but low or absent in normal tissues. Our study aimed to develop a novel FAP-specific tracer, namely [18F]FAP-2286, and evaluated its performance in comparison with well-established agents such as [18F]FAPI-42 and [68Ga]Ga-FAP-2286 in preclinical research, as well as 2-[18F]FDG in pilot clinical study. Methods [18F]FAP-2286 was manually synthesized in accordance with Good Manufacturing Practice (GMP). Subsequent investigations encompassed cell uptake, competitive binding affinity, internalization and efflux assays using HT-1080hFAP cell lines. PET imaging and biodistribution studies were conducted in HEK-293ThFAP, A549hFAP, HT-1080hFAP tumor-bearing mice as well as HEK-293T, A549 and HT-1080 control groups. Furthermore, clinical evaluation of [18F]FAP-2286 was performed in fifteen patients with various cancers compared to 2-[18F]FDG PET. Results The radiolabeling yield of [18F]FAP-2286 was 30.53 ± 5.20%, with a radiochemical purity exceeding 97%. In cell assays, [18F]FAP-2286 showed specific uptake, high internalization fraction and low cellular efflux. Rapid tumor uptake and satisfactory tumor retention was observed on micro-PET imaging and cancer patients. Meanwhile, the clinical research demonstrated that [18F]FAP-2286 may represent an alternative for low glucose-metabolism malignant tumors PET imaging such as gastric cancers. Conclusion [18F]FAP-2286 showed superior imaging quality including rapid and high target uptake and satisfactory retention in both tumor-bearing mice and cancer patients. It may emerge as a promising candidate for early or delayed phase imaging and 2-[18F]FDG non-avid cancers PET scan.
- 8 February 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (7) , 2012-2022
Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients
Purpose Fibroblast-activated protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of many solid cancers, but low or absent in normal tissues. Our study aimed to develop a novel FAP-specific tracer, namely [18F]FAP-2286, and evaluated its performance in comparison with well-established agents such as [18F]FAPI-42 and [68Ga]Ga-FAP-2286 in preclinical research, as well as 2-[18F]FDG in pilot clinical study. Methods [18F]FAP-2286 was manually synthesized in accordance with Good Manufacturing Practice (GMP). Subsequent investigations encompassed cell uptake, competitive binding affinity, internalization and efflux assays using HT-1080hFAP cell lines. PET imaging and biodistribution studies were conducted in HEK-293ThFAP, A549hFAP, HT-1080hFAP tumor-bearing mice as well as HEK-293T, A549 and HT-1080 control groups. Furthermore, clinical evaluation of [18F]FAP-2286 was performed in fifteen patients with various cancers compared to 2-[18F]FDG PET. Results The radiolabeling yield of [18F]FAP-2286 was 30.53 ± 5.20%, with a radiochemical purity exceeding 97%. In cell assays, [18F]FAP-2286 showed specific uptake, high internalization fraction and low cellular efflux. Rapid tumor uptake and satisfactory tumor retention was observed on micro-PET imaging and cancer patients. Meanwhile, the clinical research demonstrated that [18F]FAP-2286 may represent an alternative for low glucose-metabolism malignant tumors PET imaging such as gastric cancers. Conclusion [18F]FAP-2286 showed superior imaging quality including rapid and high target uptake and satisfactory retention in both tumor-bearing mice and cancer patients. It may emerge as a promising candidate for early or delayed phase imaging and 2-[18F]FDG non-avid cancers PET scan.
- Open Access
- 5 February 2024
- Published by Springer Nature in Research Square
Preclinical evaluation and first-in-human study of Al18F-FAP-NUR for PET imaging cancer-associated fibroblasts
Background Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. 68Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel 18F-labeled FAP-targeting peptide. Methods Al18F-FAP-NUR was radiolabeled with 18F using an Al18F complex on a modified GE TRACERlab FXFN synthesis platform. The 18F-labeled peptide was evaluated against 68Ga-FAP-2286, a 68Ga-labeled FAP-targeting peptide, in biochemical and cellular assays, ex vivo biodistribution studies, and in vivo micro-PET imaging. Additionally, successful first-in-human imaging of the 18F-labeled peptide was performed in two patients with breast cancer and lung cancer, respectively. Results Al18F-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to 68Ga-FAP-2286, the 18F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, Al18F-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of Al18F-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. Conclusion Based on the physical imaging properties and longer half-life of 18F, Al18F-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation.
- 5 February 2024
- Published by Springer Nature in Research Square
Open AccessPreclinical evaluation and first-in-human study of Al18F-FAP-NUR for PET imaging cancer-associated fibroblasts
Background Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. 68Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel 18F-labeled FAP-targeting peptide. Methods Al18F-FAP-NUR was radiolabeled with 18F using an Al18F complex on a modified GE TRACERlab FXFN synthesis platform. The 18F-labeled peptide was evaluated against 68Ga-FAP-2286, a 68Ga-labeled FAP-targeting peptide, in biochemical and cellular assays, ex vivo biodistribution studies, and in vivo micro-PET imaging. Additionally, successful first-in-human imaging of the 18F-labeled peptide was performed in two patients with breast cancer and lung cancer, respectively. Results Al18F-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to 68Ga-FAP-2286, the 18F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, Al18F-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of Al18F-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. Conclusion Based on the physical imaging properties and longer half-life of 18F, Al18F-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation.